Design and Characterization of Canagliflozin Nanosuspension for Solubility Enhancement

Ritesh Patel, Dr. Ashish Ashok Gawai, Dr.G. Jagadish G. Srikanth, Dr.Gajula Nagaraju, Km Nandini

Design and Characterization of Canagliflozin Nanosuspension for Solubility Enhancement

Authors

Ritesh Patel, Dr. Ashish Ashok Gawai, Dr.G. Jagadish G. Srikanth, Dr.Gajula Nagaraju, Km Nandini

Keywords:

Box Behnken design. nanosuspension, canagliflozin, particle size, zeta potential

Abstract

Introduction: Canagliflozin is a dual sodium-glucose co-transporter 1 as well as 2 (SGLT1 and SGLT2) inhibitor. Sodium-dependent glucose transporter 2 (SGLT2) plays an important role in the regulation of blood glucose. It is indicated to treattype 2 diabetes mellitus. The absolute bioavailability of oral canagliflozin was approximately 25%. It is classified as BCS class II drug and has limited bioavailability due to poor aqueous solubility.

References

Akula G, Sapavatu SN, Jadi RK, Battineni JK, Boggula N. Analytical method development and validation for the estimation of tramadol in bulk and its formulations by UV-spectroscopy. Journal of Advanced Scientific Research. 2021 May 31;12(02):77-83.

Downloads

Published

2023-04-20

How to Cite

Ritesh Patel, Dr. Ashish Ashok Gawai, Dr.G. Jagadish G. Srikanth, Dr.Gajula Nagaraju, Km Nandini. (2023). Design and Characterization of Canagliflozin Nanosuspension for Solubility Enhancement . Journal of Computational Analysis and Applications (JoCAAA), 31(4), 2737–2744. Retrieved from https://eudoxuspress.com/index.php/pub/article/view/5189